Researchers led by Ricardo Battaglino, PhD, with the University of Minnesota Medical School, see significant promise for the anti-cancer drug apilimod. The university recently reported that early results show that apilimod is five times more effective in treating cell cultures with COVID-19 as compared to remdesivir. Will this benefit translate to clinical trials? In the power of science, Sanford Burnham Prebys Medical Discovery Institute identified apilimod as one of 21 drugs that could strongly act against SARS-CoV-2, the virus behind COVID-19.
The professor and vice-chair of research in the Department of Rehabilitation Medicine recently articulated the powerful findings, “That means that this drug is more specific.” Dr. Battaglino continued, “This comparison is something that we need to do because remdesivir is the current standard of care, and this drug needs to perform better than that or the same, in order to be considered a good therapeutic candidate.”
The University of Minnesota team including Battaglino, Leslie Morse, DO, professor and head of the Department of Rehabilitation Medicine, and Vadim Gurvich, PhD, MBA, an associate professor in the College ...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).